← All reports

Evolocumab reduces the risk of cardiovascular events in patients with diabetes without known significant atherosclerosis.

HealthcareScienceSep 21, 2026score 0.172 posts · 0 replies across 1 instances
The thread discusses a study on the effectiveness of Evolocumab in reducing cardiovascular events in patients with diabetes who do not have known significant atherosclerosis. The posts share the same link, suggesting a focus on the study's findings and implications for medical treatment.

Claims

Evolocumab reduces the risk of cardiovascular events in patients with diabetes without known significant atherosclerosis.
Parent: HealthcareEntity: EvolocumabImpact: positiveDate: Sep 21, 2026Target: Evolocumab's effectiveness in reducing cardiovascular events

Source posts

@[email protected]
Evolocumab and Cardiovascular Events in Patients With Diabetes Without Known Significant Atherosclerosis https://zurl.co/PMGQj
0 boosts · 0 favs · 0 replies · Sep 21, 2026
@[email protected]
Evolocumab and Cardiovascular Events in Patients With Diabetes Without Known Significant Atherosclerosis https://zurl.co/nXRsN
0 boosts · 0 favs · 0 replies · Sep 21, 2026